No Data
No Data
Express News | OS Therapies Shares Are Trading Higher After the Company Announced the Completion of Its Phase 2b Clinical Trial for OST+HER2 in Recurred Osteosarcoma and Is Preparing to Request an FDA Type C Meeting to Adjust Protocol. It's Data Analysis and Topline...
12 Health Care Stocks Moving In Thursday's Intraday Session
Express News | Os Therapies Inc - to Request Type C Meeting With FDA
Express News | Os Therapies Inc - to Ring Closing Bell at NYSE on Oct 3, 2024
Express News | Os Therapies Announces Last Patient Enrolled in Ost-Her2 Osteosarcoma Phase 2B Clinical Trial Completes Last Patient Visit
OS Therapies Is Maintained at Buy by EF Hutton
No Data
No Data
景川 : Good time to buy~